Browse articles from EyeWorld.org related to IOLs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ New drop for temporary presbyopia relief approved ➤ First-in-human results for accommodating IOL ➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy ➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain ➤ Company news ➤ ASCRS news and events
➤ FDA review extended for dry eye disease treatment ➤ Key data gathered for expected NDA submission ➤ Phase 2b results for GA treatment ➤ Phase 3 studies discontinued for thyroid eye disease ➤ ASCRS news and events
The University of Washington ophthalmology residents reviewed “Long term efficacy and safety of iris-claw phakic intraocular lens in the management of post keratoplasty astigmatism” from the December issue of the Journal of Cataract & Refractive Surgery.
While not a common approach or its primary indication, the ICL (STAAR Surgical) can be used as a supplementary/piggyback IOL in some patients. Three physicians discussed how this off-label approach to using the ICL is opening doors to treat certain patients.
It was a successful year for the Journal of Cataract & Refractive Surgery (JCRS), the official journal of ASCRS and ESCRS, and JCRS Online Case Reports (JCRO), an online-only companion journal to JCRS. To celebrate this success, EyeWorld is featuring some of the most-viewed papers.
Nailing outcomes with presbyopia-correcting IOLs is important for many reasons—one of them being patient expectations, as they are paying out of pocket for an advanced-technology lens. But even when you’ve had an excellent surgery, postop complaints can trickle in, and the possible causes for the dissatisfaction are diverse.
➤ FDA approves treatment for macular edema following RVO ➤ New cyclosporine product receives approval for dry eye ➤ First human implant of 3D-bioprinted cornea ➤ Topline results from Phase 3 trial for Stargardt disease ➤ First patient treated with IDE glaucoma therapy ➤ Enrollment complete for Phase 2 trial for geographic atrophy treatment ➤ First patient implanted with investigational glaucoma shunt in trial ➤ Positive review of Phase 3 pivotal trial for AMD ➤ Company news ➤ ASCRS news and events
➤ Topline Phase 3 results for low-dose atropine drop ➤ 12-month data from prospective pilot study assessing aqueous shunt ➤ 5-year follow-up data supports safety, tolerability of investigational retinitis pigmentosa treatment. ➤ Randomization achieved in registrational trial for wet AMD therapy ➤ BLA submitted for thyroid eye disease treatment ➤ Company news ➤ ASCRS news and events
➤ New trifocal receives FDA approval ➤ Robotic system completes its first cataract surgery ➤ Interim results from first-in-human bimatoprost-IOL system ➤ Reproducible regenerative effects observed in preclinical glaucoma model ➤ Phase 3 program begins for intravitreal insert treating wet AMD, DME ➤ ASCRS news and events
EyeWorld reports on the BRiCS Summit, which took place October 3–5 in Chicago, Illinois. What the course really boils down to is increasing confidence in the premium IOL practice through education, resources, and networking connections, according to Vance Thompson, MD, chair, and William Wiley, MD, co-director.
Get the latest ophthalmology news delivered to your inbox every Friday.